ELI LILLY AND COMPANY Proceeds from Sale of Intangible Assets
ELI LILLY AND COMPANY (LLY) reported Proceeds from Sale of Intangible Assets of $218.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2026-02-12
- ELI LILLY AND COMPANY proceeds from sale of intangible assets for the quarter ending 2024-12-31 was $70.10M.
- ELI LILLY AND COMPANY proceeds from sale of intangible assets for the quarter ending 2023-12-31 was -$300.00K, a 101.00% decline year-over-year.
- ELI LILLY AND COMPANY proceeds from sale of intangible assets for the quarter ending 2022-12-31 was $30.00M.
- ELI LILLY AND COMPANY proceeds from sale of intangible assets for the quarter ending 2013-12-31 was $0.00.
- ELI LILLY AND COMPANY proceeds from sale of intangible assets for fiscal 2025 was $218.00M, a 63.73% decline from fiscal 2024.
- ELI LILLY AND COMPANY proceeds from sale of intangible assets for fiscal 2024 was $601.00M, a 62.53% decline from fiscal 2023.
- ELI LILLY AND COMPANY proceeds from sale of intangible assets for fiscal 2023 was $1.60B, a 1574.32% increase from fiscal 2022.
- ELI LILLY AND COMPANY proceeds from sale of intangible assets for fiscal 2022 was $95.80M, a 55.65% decline from fiscal 2021.
| Period end | Proceeds from Sale of Intangible Assets 1 month | Proceeds from Sale of Intangible Assets 3 month | Proceeds from Sale of Intangible Assets 9 month | Proceeds from Sale of Intangible Assets 12 month | Proceeds from Sale of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $218.00M 10-K · filed 2026-02-12 | ||||
| 2024-12-31 | $70.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $601.00M 10-K · filed 2026-02-12 | $601.30M 10-K · filed 2025-02-19 | ||
| 2024-09-30 | $530.90M 10-Q · filed 2024-10-30 | ||||
| 2023-12-31 | -$300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.60B 10-K · filed 2026-02-12 | $1.60B 10-K · filed 2024-02-21 | ||
| 2023-09-30 | $1.60B 10-Q · filed 2024-10-30 | ||||
| 2022-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $95.80M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | $65.80M 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | $216.00M 10-K · filed 2024-02-21 | ||||
| 2014-12-31 | $0.00 10-K · filed 2015-02-19 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $0.00 10-K · filed 2015-02-19 | |||
| 2013-09-30 | $0.00 10-Q · filed 2013-10-30 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $1.21B 10-K · filed 2015-02-19 | |||
| 2012-09-30 | $1.21B 10-Q · filed 2013-10-30 | ||||
| 2012-08-31 | -$1.21B 10-Q · filed 2014-07-28 | ||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $0.00 10-K · filed 2014-02-19 | |||
| 2011-09-30 | $0.00 10-Q · filed 2012-10-26 | ||||
| 2010-12-31 | $0.00 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |